Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon

被引:35
|
作者
Haustein, KO [1 ]
机构
[1] Univ Jena Klinikum, D-99089 Erfurt, Germany
来源
SEMINARS IN THROMBOSIS AND HEMOSTASIS | 1999年 / 25卷 / 01期
关键词
phenprocoumon; phytomenadion; pharmacokinetics; prothrombin time; drug interactions;
D O I
10.1055/s-2007-996417
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anticoagulants of the cumarin-type (warfarin, phenprocoumon, and acenocoumarol) are drugs for the long-term treatment and prevention of thromboembolic disorders. Because of their narrow therapeutic range, many patients have bleedings of variable severity or have recurrent thrombotic events. For this reason, the study of the pharmacokinetic parameters of phenprocoumon (PPC), considering its influence on blood clotting factors, is of high interest. The elimination kinetics of PPC, its interaction with phytomenadion (vitamin K), and the pharmacokinetic behavior of the anticoagulant under steady-state conditions have been investigated in studies with healthy volunteers and patients taking anticoagulants, The maintenance dose and the plasma levels of PPC were correlated with prothrombin time (PT) in 89 patients treated with PPC, Varying parameters in each patient (e.g., elimination kinetics of PPC, activity of the cumarin-dependent blood-clotting factors, endogenous phytomenadion stores), render it impossible to use a different means of monitoring than that of PT determination.
引用
收藏
页码:5 / 11
页数:7
相关论文
共 50 条
  • [41] Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)
    Steele, N. L.
    Plumb, J. A.
    Vidal, L.
    Tjornelund, J.
    Knoblauch, P.
    Buhl-Jensen, P.
    Molife, R.
    Brown, R.
    de Bono, J. S.
    Evans, T. R. J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (06) : 1273 - 1279
  • [42] The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
    Nakai, Kiyohiko
    Tobinai, Masato
    Hashimoto, Junko
    Iida, Satofumi
    Kawanishi, Takehiko
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2016, 41 (02) : 139 - 147
  • [43] Pharmacokinetic and pharmacodynamic properties of β-hydroxyphospho-carnitine
    Mendoza-Rivera, Brissa
    Reyes-Esparza, Jorge
    De La Cruz Cordero, Ricardo
    Rodriguez-Fragoso, Lourdes
    FASEB JOURNAL, 2014, 28 (01):
  • [44] RELATIONSHIP OF PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF THE ORGANIC NITRATES
    THADANI, U
    WHITSETT, T
    CLINICAL PHARMACOKINETICS, 1988, 15 (01) : 32 - 43
  • [45] Fluoroquinolones - Pharmacokinetic properties and new pharmacodynamic concepts
    BergogneBerezin, E
    PRESSE MEDICALE, 1997, 26 (12): : 577 - 582
  • [46] Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine
    El-Eraky, H
    Thomas, SHL
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (02) : 198 - 204
  • [47] Pharmacodynamic and Pharmacokinetic Properties of EnoxaparinImplications for Clinical Practice
    Jawed Fareed
    Debra Hoppensteadt
    Jeanine Walenga
    Omer Iqbal
    Qing Ma
    Walter Jeske
    Taqdees Sheikh
    Clinical Pharmacokinetics, 2003, 42 : 1043 - 1057
  • [48] Pharmacokinetic and pharmacodynamic properties important for inhaled corticosteroids
    Hochhaus, Guenther
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2007, 98 (02) : S7 - S15
  • [49] Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
    Schachter, M
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2005, 19 (01) : 117 - 125
  • [50] Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems
    Glassman, Patrick M.
    Muzykantov, Vladimir R.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2019, 370 (03): : 570 - 580